Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 6/20 | 0.59 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 5/20 | 0.59 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.59 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.59 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.59 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | FAAH | O00519 | 1/20 | 0.71 |
| ▸ | TP53 | P04637 | 1/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | CES2 | O00748 | 3/20 | 0.62 |
| ▸ | CES1 | P23141 | 3/20 | 0.62 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.59 |
| ▸ | PPARD | Q03181 | 6/20 | 0.59 |
| ▸ | PPARA | Q07869 | 6/20 | 0.59 |
| ▸ | TSHR | P16473 | 4/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29863502 | 1.00 | SOAT1 (0.71) | SOAT1MEN1KMT2AFAAHTP53 | |
| Hydrochloric Acid SCHEMBL28977480 | 1.00 | SOAT1 (0.71) | SOAT1MEN1KMT2AFAAHTP53 | |
| Hydrochloric Acid SCHEMBL30958746 | 1.00 | SOAT1 (0.71) | SOAT1MEN1KMT2AFAAHTP53 | |
| Hydrochloric Acid SCHEMBL6941901 | 1.00 | SOAT1 (0.71) | SOAT1MEN1KMT2AFAAHTP53 | |
| Hydrochloric Acid SCHEMBL31367850 | 1.00 | SOAT1 (0.71) | SOAT1MEN1KMT2AFAAHTP53 | |
| Palmitamide SCHEMBL25349110 | 1.00 | SOAT1 (0.71) | SOAT1MEN1KMT2AFAAHTP53 | |
| Octadecanoic Acid Amide SCHEMBL5791921 | 1.00 | SOAT1 (0.71) | SOAT1MEN1KMT2AFAAHTP53 | |
| Tetradecanamide SCHEMBL30958755 | 1.00 | SOAT1 (0.71) | SOAT1MEN1KMT2AFAAHTP53 | |
| Hydrochloric Acid SCHEMBL30958748 | 1.00 | SOAT1 (0.71) | SOAT1MEN1KMT2AFAAHTP53 | |
| Tetradecanamide SCHEMBL28136606 | 1.00 | SOAT1 (0.71) | SOAT1MEN1KMT2AFAAHTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240425517-A1 | NOVEL COMPOUND FOR DEGRADATION OF TARGET PROTEIN OR POLYPEPTIDE BY POLYUBIQUITINATION | PRAZER THERAPEUTICS INC. (KR) | 2024-12-26 | — | — | US | claimed |
| CN-103724573-B | A kind of preparation method of amphipathic copolymerization network | DONGHUA UNIVERSITY (CN) | 2016-01-20 | — | — | CN | claimed |
| CN-103865067-B | A kind of preparation method of amphipathic copolymerization network | DONGHUA UNIVERSITY (CN) | 2016-01-06 | — | — | CN | claimed |
| CN-104592532-A | Amphiphilic copolymer network and preparation method thereof | NAT UNIV DONG HWA | 2015-05-06 | — | — | CN | claimed |
| CN-103865067-A | Method for preparing amphiphilic copolymeric network | UNIV DONGHUA | 2014-06-18 | — | — | CN | claimed |
| CN-103724573-A | Method for preparing amphipathic copolymerization network | UNIV DONGHUA | 2014-04-16 | — | — | CN | claimed |
| US-20240425517-A1 | NOVEL COMPOUND FOR DEGRADATION OF TARGET PROTEIN OR POLYPEPTIDE BY POLYUBIQUITINATION | PRAZER THERAPEUTICS INC. (KR) | 2024-12-26 | — | — | US | disclosed |
| CN-116437913-A | Pharmaceutical compounds for treating complement-mediated disorders | 艾其林医药公司 | 2023-07-14 | — | — | CN | disclosed |
| CN-113717161-B | Nitrogen-containing saturated heterocyclic compound, preparation method thereof, pharmaceutical composition and application | 广州费米子科技有限责任公司 | 2023-06-09 | — | — | CN | disclosed |
| CN-114685505-A | Imidazopyrrolopyridines as JAK family kinase inhibitors | 詹森药业有限公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-110312719-B | Imidazopyrrolopyridines as JAK family kinase inhibitors | 詹森药业有限公司 | 2022-04-15 | — | — | CN | disclosed |
| CN-113717161-A | Nitrogen-containing saturated heterocyclic compound and preparation method, pharmaceutical composition and application thereof | 广州费米子科技有限责任公司 | 2021-11-30 | — | — | CN | disclosed |
| CN-113226296-A | SSAO inhibitors and uses thereof | 梅塔科林公司 | 2021-08-06 | — | — | CN | disclosed |
| CN-101351443-A | Process for preparing sulfonamides | BASF AG (DE) | 2009-01-21 | — | — | CN | disclosed |
| CN-101218218-A | Novel Pyrocatechol Derivatives | NOVARTIS AG (CH) | 2008-07-09 | — | — | CN | disclosed |
| CN-1839194-A | Treatment of crude oil fractions, fossil fuels and products thereof | MARK CULLEN (US) | 2006-09-27 | — | — | CN | disclosed |
| CN-1169791-C | Novel acetamide derivatives and protease inhibitors | �ձ���ҩ��ʽ���� | 2004-10-06 | — | — | CN | disclosed |
| CN-1312805-A | Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake | SEARLE & CO (US) | 2001-09-12 | — | — | CN | disclosed |
| CN-1229405-A | Novel acetamide derivatives and protease inhibitors | NIPPON KAYAKU KK (JP) | 1999-09-22 | — | — | CN | disclosed |
| CN-1100734-A | Process for producing cross-linked monodispersed polymeric particles | GEN ELECTRIC (US) | 1995-03-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240425517-A1 | NOVEL COMPOUND FOR DEGRADATION OF TARGET PROTEIN OR POLYPEPTIDE BY POLYUBIQUITINATION | ADRM1, SUMO1, SUMO2 | PPARG 3040/4885HDAC11 1761/4885ESR1 2938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.